Evidence map›Paper›PMID 41537429›Full record

RevieweLife2026

Trained immunity in acute and chronic neurological diseases.

Sijia Zhang, Arthur Liesz

Abstract readReview
In one paragraph

Review in eLife, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Sijia ZhangInstitute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany.
Arthur LieszInstitute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany.ORCID https://orcid.org/0000-0002-9069-2594

Funding

European Research Council Consolidator GRANT TRAINED ID 101229857German Research Foundation EXC 2145 SyNergy
6 · The paper itself

Abstract

Trained immunity, the long-term reprogramming of innate immune cells to elicit an enhanced response upon subsequent challenges, has become a key concept in understanding a wide range of pathologies, including both acute and chronic inflammatory disorders. Recent evidence suggests that trained immunity also plays a significant role in the development and progression of various neurological disorders and related comorbidities, in which brain pathology can lead to trained immunity. This review summarizes the current understanding of trained immunity within both brain-resident immune cells and myeloid-derived innate immune cells, focusing on their roles in neurological disorders, such as ischemic brain injury, Parkinson's disease, and Alzheimer's disease. Additionally, we explore the heterogeneity of trained immunity across different conditions and its potential applications in clinical neurology.

Indexed as

Immunity, InnateNervous System DiseasesTrained ImmunityAcute DiseaseAnimalsBrainChronic DiseaseHumansalzheimer's diseasebrain disordersimmunologyinflammationinnate immunityneuroscienceparkinson's diseasestroketrained immunity

Identifiers

PMID41537429
PMCPMC12807454

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.